HGF/c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
=== Pregnancy and breastfeeding === Although there are no major human studies of prednisolone use in pregnant women, studies in several animals show that it may cause birth defects including increased likelihood of cleft palate. Prednisolone is found in the breast milk of mothers taking prednisolone.
=== Electrochemical skin conductance === Electrochemical skin conductance (ESC) is an objective, quantitative, non-invasive method for the assessment of sudomotor function that utilizes chronoamperometry (the application of rectangular direct current (DC) pulses of varying voltage amplitudes) to electrically stimulate eccrine sweat glands, and reverse iontophoresis (the migration of electrolytes from the human sweat to the electrodes) for quantitative measurement of the resulting flow of Cl- ions. ESC can be measured with the use of a medical device called Sudoscan. A novel electrochemical model of the skin was devised, reproducing the behavior of chloride ions and the properties of their ion channel to develop a computational tool for measuring chloride ion flow through a sweat gland in response to an imposed voltage. In vitro electrochemical studies were then carried out in conventional three-electrode cells to identify the origin of currents measured upon the application of low voltage potentials with variable amplitudes to stainless steel electrodes applied to the skin during clinical tests. These studies also evaluated the influence of different parameters in sweat (e.g., urea, lactate) on the obtained currents. These studies formed the basis for the ESC methodology of measuring sudomotor function. The flow of Cl− ions in the sweat secreted from the activated sweat glands are captured by the anode. This process is repeated twice for the feet and twice for the hands with the right and left electrodes alternating as the anode and cathode.
Cold air damming typically happens in the mid-latitudes as this region lies within the Westerlies, an area where frontal intrusions are common. When the Arctic oscillation is negative and pressures are higher over the poles, the flow is more meridional, blowing from the direction of the pole towards the equator, which brings cold air into the mid-latitudes. Cold air damming is observed in the southern hemisphere to the east of the Andes, with cool incursions seen as far equatorward as the 10th parallel south. In the northern hemisphere, common situations occur along the east side of ranges within the Rocky Mountains system over the western portions of the Great Plains, as well as various other mountain ranges (such as the Cascades) along the west coast of the United States. The initial is caused by the poleward portion of a split upper level trough, with the damming preceding the arrival of the more equatorward portion. Some of the cold air damming events which occur east of the Rockies continue southward to the east of the Sierra Madre Oriental through the coastal plain of Mexico through the Isthmus of Tehuantepec. Further funneling of cool air occurs within the Isthmus, which can lead to winds of gale and hurricane-force, referred to as a Tehuantepecer. Other common instances of cold air damming take place on the coastal plain of east-central North America, between the Appalachian Mountains and Atlantic Ocean. In Europe, areas south of the Alps can be prone to cold air damming. In Asia, cold air damming has been documented near Taiwan and the Korean Peninsula.
In New Zealand, it is not included in the Misuse of Drugs Act 1975, but is illegal, as it is similar to controlled substances. In Canada, mephedrone is not explicitly listed in any schedule of the Controlled Drugs and Substances Act, but "amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues" are included in Section 19 of Schedule I of the act. Cathinone and methcathinone are listed in separate sections of Schedule III, while diethylpropion and pyrovalerone (also cathinones), are listed in separate sections of Schedule IV, each without language to capture analogues, isomers, etc. Mephedrone is considered a controlled substance by Health Canada. In a report by the Canadian Medical Association in 2010, one lawyer was quoted as suggesting that mephedrone was less popular in Canada than in the U.K. because "there's a provision in the substance act that says analogues of certain drugs and other similar drugs may be illegal too,"; on the other hand, the assistant director of the Centre for Addictions Research of British Columbia suggested there was a lack of "clear illegality". There have been several media reports of the Canadian police seizing mephedrone, but no reports of any successful prosecution of a Controlled Drugs and Substances Act offence implicating mephedrone. Mephedrone is also currently scheduled in the United States as of 2011.
237Np decays via the neptunium series, which terminates with thallium-205, which is stable, unlike most other actinides, which decay to stable isotopes of lead. Until the discovery of its alpha decay (with an extremely long half-life), the series was thought to end with bismuth-209. In 2002, 237Np was shown to be capable of sustaining a chain reaction with fast neutrons, as in a nuclear weapon, with a critical mass of around 60 kg. However, it has a low probability of fission on bombardment with thermal neutrons, which makes it unsuitable as a fuel for light water nuclear power plants (as opposed to fast reactor or accelerator-driven systems, for example).
Sources: en.wikipedia.org
Pitolisant is an inverse agonist (antagonist) of the histamine H3 autoreceptor. As such, pitolisant is an antihistamine medication that also belongs to the class of CNS stimulants. Pitolisant is also considered a medication of eugeroic class, which means that it promotes wakefulness and alertness. Pitolisant is the first wakefulness-promoting agent that acts by blocking the H3 autoreceptor. Pitolisant has been shown to be effective and well-tolerated for the treatment of narcolepsy with or without cataplexy. Pitolisant is the only non-controlled anti-narcoleptic drug in the United States. It has shown minimal abuse risk in studies. Blocking the histamine H3 autoreceptor increases the activity of histamine neurons in the brain. The H3 autoreceptors regulate histaminergic activity in the central nervous system (and to a lesser extent, the peripheral nervous system) by inhibiting histamine biosynthesis and release upon binding to endogenous histamine. By preventing the binding of endogenous histamine at the H3, as well as producing a response opposite to that of endogenous histamine at the receptor (inverse agonism), pitolisant enhances histaminergic activity in the brain.
Standard reuptake inhibitors are believed to act simply as competitive substrates that work by binding directly to the plasmalemma transporter of the neurotransmitter in question. They occupy the transporter in place of the respective neurotransmitter and competitively block it from being transported from the nerve terminal or synapse into the pre-synaptic neuron. With high enough doses, occupation becomes as much as 80–90%. At this level of inhibition, the transporter will be considerably less efficient at removing excess d from the synapse and this causes a substantial increase in the extracellular concentrations of the neurotransmitter and therefore an increase in overall neurotransmission.
H2NCH2CH2NH2 + 4 CH2O + 4 NaCN + 4 H2O → (NaO2CCH2)2NCH2CH2N(CH2CO2Na)2 + 4 NH3 (NaO2CCH2)2NCH2CH2N(CH2CO2Na)2 + 4 HCl → (HO2CCH2)2NCH2CH2N(CH2CO2H)2 + 4 NaCl This process is used to produce about 80,000 tonnes of EDTA each year. Impurities cogenerated by this route include glycine and nitrilotriacetic acid; they arise from reactions of the ammonia coproduct.
The gastrointestinal hormones (or gut hormones) constitute a group of hormones secreted by enteroendocrine cells in the stomach, pancreas, and small intestine that control various functions of the digestive organs. Later studies showed that most of the gut peptides, such as secretin, cholecystokinin or substance P, were found to play a role of neurotransmitters and neuromodulators in the central and peripheral nervous systems. Enteroendocrine cells do not form glands but are spread throughout the digestive tract. They exert their autocrine and paracrine actions that integrate gastrointestinal function.
Bupropion has a particularly odd pattern of inducing DAT inhibition, since it displays markedly enhanced binding affinity towards the DAT-(NET S1) mutant (DAT with NET primary binding site) over normal (wild-type) DAT, and noticeably diminished binding affinity towards the NET-(DAT S1) mutant (NET with DAT primary binding site) over regular (wild-type) NET. In spite of clear preference for NET binding site by itself, bupropion retains overall preference for complete DAT, implying that bupropion may make use of non-binding sites on the DAT molecule to exert its own binding, as well as the potential of augmented affinity for NET if its binding site is otherwise conformationally exposed. Bupropion has been claimed to be a sigma σ1 receptor agonist. Its antidepressant-like effects in rodents depend on σ1 receptor activation. They are enhanced and inhibited by σ1 receptor agonists and antagonists, respectively. However, no data on the binding or functional effects of bupropion at the human sigma receptors seem to be available. In any case, bupropion has been reported to bind to rodent σ1 receptors with IC50Tooltip half-maximal inhibitory concentration values of 580 to 2,100 nM. In contrast to many other phenethylamines and amphetamines, bupropion is not an agonist of the trace amine-associated receptor 1 (TAAR1). Bupropion has been found to have a mixture of anti-inflammatory and pro-inflammatory activity through modulation of the immune system. One such mechanism underlying these effects may be reduced levels of the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα).
Sources: en.wikipedia.org
In a later discussion about this research, Turner reiterated the importance of protecting pregnant women from any infection, and if vaccines were in short supply, prioritising them for "access to antivirals and ventilators in hospital intensive care units if they get sick".
=== Health Risks === Studies show that xenografts can be used, however they are closely monitored due to their risk of rejection. Zoonoses, which are diseases that arise from the crossing of animal and human tissue, pose a threat to the success of xenograft implantation. Specifically, these diseases are referenced as "xenozoonoses". They can be categorized in 3 different groups: viral infection, prion-mediated infection, and bacterial infection. They have the potential to create a public health risk if they are not closely monitored, as they can cause diseases to be more easily transmissible through different species.
=== Sheep === In sheep, ketosis, evidenced by hyperketonemia with beta-hydroxybutyrate in blood over 0.7 mmol/L, is referred to as pregnancy toxemia. This may develop in late pregnancy in ewes bearing multiple fetuses and is associated with the considerable metabolic demands of the pregnancy. In ruminants, because most glucose in the digestive tract is metabolized by rumen organisms, glucose must be supplied by gluconeogenesis. Pregnancy toxemia is most likely to occur in late pregnancy due to metabolic demand from rapid fetal growth and may be triggered by insufficient feed energy intake due to weather conditions, stress or other causes. Prompt recovery may occur with natural parturition, Caesarean section or induced abortion. Prevention through appropriate feeding and other management is more effective than treatment of advanced stages of pregnancy toxemia.
Colin Skinner (born 1965) is a British author, adventurer and molecular biologist who is attempting to walk around the world. As of mid-2014, he has walked over 14,500 miles (23,300 km) and has crossed Great Britain, Iceland, United States and New Zealand. He has used the walks to raise money and awareness for various causes, including conservation biology, people with disabilities, cancer relief, AIDS, and hospice.
adduct A distinct chemical species that is the sole product of an addition reaction between two other distinct reactant species, in which all of the atoms comprising the reactants are retained in the single product. Changes in connectivity may occur, but there is no loss of any of the original atoms and no gain of atoms that are not present in the reactant molecules. Stoichiometries other than 1:1 are also possible, e.g. a bis-adduct (2:1).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.